[1] CHAMBERS D C,CHERIKH W S,HARHAY M O,et al.The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation:Thirty-sixth adult lung and heart-lung transplantation Report-2019; Focus theme:Donor and recipient size match[J].J Heart Lung Transplant,2019,38(10):1042-1055.
[2] GULER S A,CORTE T J.Interstitial lung disease in 2020:a history of progress[J].Clin Chest Med,2021,42(2):229-239.
[3] KAUL B,COTTIN V,COLLARD H R,et al.Variability in global prevalence of interstitial lung disease[J].Front Med (Lausanne),2021,8:751181.
[4] 王柳盛,李惠萍.中国大陆间质性肺疾病流行病学资料及研究进展[J].中华内科杂志,2014(8):3.
[5] TRAVIS W D,COSTABEL U,HANSELL D M,et al.An official American Thoracic Society/European Respiratory Society statement:Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias[J].Am J Respir Crit Care Med,2013,188(6):733-748.
[6] RAGHU G,REMY-JARDIN M,RYERSON C J,et al.Diagnosis of Hypersensitivity Pneumonitis in Adults.An Official ATS/JRS/ALAT Clinical Practice Guideline[J].Am J Respir Crit Care Med,2020,202(3):e36-e69.
[7] LEUNG C C,YU I T,CHEN W.Silicosis[J].Lancet,2012,379(9830):2008-2018.
[8] PUGASHETTI J V,KITICH A,ALQALYOOBI S,et al.Derivation and validation of a diagnostic prediction tool for interstitial lung disease[J].Chest,2020,158(2):620-629.
[9] SVERZELLATI N,GUERCI L,RANDI G,et al.Interstitial lung diseases in a lung cancer screening trial[J].Eur Respir J,2011,38(2):392-400.
[10] SKOLNIK K,RYERSON C J.Unclassifiable interstitial lung disease:a review[J].Respirology,2016,21(1):51-56.
[11] FLAHERTY K R,TOEWS G B,TRAVIS W D,et al.Clinical significance of histological classification of idiopathic interstitial pneumonia[J].Eur Respir J,2002,19(2):275-283.
[12] LAZOR R,VANDEVENNE A,PELLETIER A,et al.Cryptogenic organizing pneumonia.Characteristics of relapses in a series of 48 patients.The Groupe d'Etudes et de Recherche sur les Maladles "Orphelines" Pulmonaires (GERM "O" P)[J].Am J Respir Crit Care Med,2000,162(2 Pt 1):571-577.
[13] RAGHU G,DEPASO W J,CAIN K,et al.Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis:a prospective double-blind,randomized,placebo-controlled clinical trial[J].Am Rev Respir Dis,1991,144(2):291-296.
[14] PLEASANTS R,TIGHE R M.Management of idiopathic pulmonary fibrosis[J].Ann Pharmacother,2019,53(12):1238-1248.
[15] NOBLE P W,ALBERA C,BRADFORD W Z,et al.Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY):two randomised trials[J].Lancet,2011,377(9779):1760-1769.
[16] LEARD L E,HOLM A M,VALAPOUR M,et al.Consensus document for the selection of lung transplant candidates:an update from the International Society for Heart and Lung Transplantation[J].J Heart Lung Transplant,2021,40(11):1349-1379.
[17] RAHIMI N,MATILLA J R,LANG G,et al.Simultaneous pectus excavatum correction and lung transplantation-A case series[J].Am J Transplant,2021,21(1):410-414.
[18] WEI D,GAO F,WU B,et al.Single versus bilateral lung transplantation for idiopathic pulmonary fibrosis[J].Clin Respir J,2019,13(6):376-383.
[19] MARTIN A K,JAYARAMAN A L,NABZDYK C G,et al.Extracorporeal membrane oxygenation in lung transplantation:analysis of techniques and outcomes[J].J Cardiothorac Vasc Anesth,2021,35(2):644-661.
[20] DIAMOND J M,LEE J C,KAWUT S M,et al.Clinical risk factors for primary graft dysfunction after lung transplantation[J].Am J Respir Crit Care Med,2013,187(5):527-534.
[21] SNELL G I,YUSEN R D,WEILL D,et al.Report of the ISHLT Working Group on Primary Lung Graft Dysfunction,part I:Definition and grading-A 2016 Consensus Group statement of the International Society for Heart and Lung Transplantation[J].J Heart Lung Transplant,2017,36(10):1097-1103.
[22] 胡春兰,于慧智,王净,等.肺移植术后原发性移植物功能障碍的危险因素研究进展[J].器官移植,2021,12(3):6.
[23] SWAMINATHAN A C,TODD J L,PALMER S M.Advances in human lung transplantation[J].Annu Rev Med,2021,72:135-149.
[24] MANGI A A,MASON D P,NOWICKI E R,et al.Predictors of acute rejection after lung transplantation[J].Ann Thorac Surg,2011,91(6):1754-1762.
[25] BERY A I,HACHEM R R.Antibody-mediated rejection after lung transplantation[J].Ann Transl Med,2020,8(6):411.
[26] LEVINE D J,GLANVILLE A R,ABOYOUN C,et al.Antibody-mediated rejection of the lung:a consensus report of the International Society for Heart and Lung Transplantation[J].J Heart Lung Transplant,2016,35(4):397-406.
[27] GLANVILLE A R,VERLEDEN G M,TODD J L,et al.Chronic lung allograft dysfunction:definition and update of restrictive allograft syndrome-A consensus report from the Pulmonary Council of the ISHLT[J].J Heart Lung Transplant,2019,38(5):483-492.
[28] BURLINGHAM W J,LOVE R B,JANKOWSKA-GAN E,et al.IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants[J].J Clin Invest,2007,117(11):3498-3506.
[29] CORRIS P A,RYAN V A,SMALL T,et al.A randomised controlled trial of azithromycin therapy in bronchiolitis obliterans syndrome (BOS) post lung transplantation[J].Thorax,2015,70(5):442-450.
[30] SHIRAISHI T,IWASAKI A.[Prevention and Treatment Strategy for Infectious Complication after Lung Transplantation] [J].Kyobu Geka,2016,69(11):900-905.
[31] YEGEN H A,LEDERER D J,BARR R G,et al.Risk factors for venous thromboembolism after lung transplantation[J].Chest,2007,132(2):547-553.
[32] KRIVOKUCA I,VAN DE GRAAF E A,VAN KESSEL D A,et al.Pulmonary embolism and pulmonary infarction after lung transplantation[J].Clin Appl Thromb Hemost,2011,17(4):421-424.
[33] CHAMBERS D C,PERCH M,ZUCKERMANN A,et al.The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation:Thirty-eighth adult lung transplantation report-2021; Focus on recipient characteristics[J].J Heart Lung Transplant,2021,40(10):1060-1072.
[34] LE PAVEC J,VALEYRE D,GAZENGEL P,et al.Lung transplantation for sarcoidosis:outcome and prognostic factors[J].Eur Respir J,2021,58(2):1-12.
[35] ROSENGARTEN D,FOX B D,FIREMAN E,et al.Survival following lung transplantation for artificial stone silicosis relative to idiopathic pulmonary fibrosis[J].Am J Ind Med,2017,60(3):248-254. |
